May 15, 2013
The Bluestone Center for Clinical Research is pleased to welcome Dr. Samit Hirawat, Senior Vice President, Global Program Head, Novartis Pharmaceuticals to the NYU College of Dentistry Tuesday, May 21st.
Samit Hirawat, M.D., joined Novartis Oncology in 2007 and is the Senior Vice President and Global Program Head for the PI3K inhibitors and CDK4/6 inhibitor development programs. As the Program Head for four compounds, Samit works closely with internal and external collaborators and investigators to development these novel compounds. This clinical development is closely aligned with the parallel generation of data to identify biomarkers that predict the activity of the drugs and aid in patient pre-selection strategies.
Prior to joining Novartis Oncology, Dr. Hirawat led the clinical development of compounds for genetic disorders such as Cystic Fibrosis and Duchenne Muscular Dystrophy in pediatric and adult populations. He worked in close collaboration with academic centers to define the endpoints for regulatory submissions for these genetic disorders. In the field of Oncology, Samit has been involved in the clinical development of HDAC inhibitors, tubulin binding agents and Topo-I inhibitors.
Dr. Hirawat received his Bachelor of Medicine and Bachelor of Surgery (M.B, B.S.) from the Sawai Man Singh Medical College in India, and completed his Internal Medicine Residency and Medical Oncology Training at North Shore University Hospital in New York. Samit is a recipient of several government grants, and academic & corporate awards.
Dr. Hirawat will discuss, “Bench to Bedside: An Industry Perspective on Drug Development” from 4:30-5:00 at the NYU College of Dentistry, 345 East 24th St. This lecture is open to the public and all are welcome to attend. Please RSVP to Dr. Patricia Corby at PC95@nyu.edu.